NewAmsterdam Pharma Company N.V. (NAMS) Spending and interest coverage
- R&D / revenue · 12 months: Value 2095.87%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 918.64%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2095.87% | Research and development expense / revenue. Period ending 2026-06-30. $149.25M ÷ $7.12M × 100 ≈ 2095.87% |
| Stock-based compensation / revenue · 12 months | 918.64% | Share-based compensation / revenue. Period ending 2026-06-30. $65.42M ÷ $7.12M × 100 ≈ 918.64% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 149.25M USD | Research and Development Expense |
| Revenue | 7.12M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 65.42M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -244.41M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $149.25M | $7.12M | $65.42M | $-244.41M | (m) | 2095.87% | 918.64% | (m) | (m) |
| 2026-03-31 | $135.09M | $22.57M | $62.21M | $-215.18M | (m) | 598.67% | 275.71% | (m) | (m) |
| 2025-12-31 | $141.83M | $22.50M | $59.42M | $-225.68M | (m) | 630.28% | 264.08% | (m) | (m) |
| 2025-09-30 | $138.13M | $35.24M | $54.82M | $-202.93M | (m) | 391.94% | 155.54% | (m) | (m) |
| 2025-06-30 | $142.86M | $64.01M | $47.80M | $-172.79M | (m) | 223.20% | 74.69% | (m) | (m) |
| 2025-03-31 | $153.73M | $47.14M | $40.91M | $-189.73M | (m) | 326.11% | 86.79% | (m) | (m) |
| 2024-12-31 | $151.41M | $45.56M | $33.62M | $-176.29M | (m) | 332.30% | 73.79% | (m) | (m) |
| 2024-09-30 | $157.80M | $33.59M | $30.21M | $-184.13M | (m) | 469.74% | 89.93% | (m) | (m) |
| 2024-06-30 | $165.47M | $7.42M | $27.61M | $-208.69M | (m) | 2228.88% | 371.85% | (m) | (m) |
| 2024-03-31 | $161.43M | $6.86M | $24.87M | $-198.60M | (m) | 2352.58% | 362.49% | (m) | (m) |
| 2023-12-31 | $159.42M | $14.09M | $24.57M | $-182.97M | (m) | 1131.47% | 174.39% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $86.74M | $102.69M | $4.12M | $-3.56M | $287.00K | 84.47% | 4.01% | -12.39× | Reported |
| 2021-12-31 | $28.97M | (m) | $1.24M | $-34.98M | $411.00K | (m) | (m) | -85.10× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |